Abstract
Epstein-Barr virus (EBV) is a common human herpesvirus that establishes latency in B cells. While EBV infection is asymptomatic for most individuals, immune-suppressed individuals are at significantly higher risk of a form of EBV latent infection in which infected B cells are reactivated, grow unchecked, and generate lymphomas. This form of latency is modeled in the laboratory by infecting B cells from the blood of normal human donorsin vitro. In this model, we identified a protein called CD226 that is induced by EBV but is not normally expressed on B cells. Rather, it is known to play a role in aggregation and survival signaling of non-B cells in the immune system. Cultures of EBV-infected cells adhere to one another in “clumps,” and while the proteins that are responsible for this cellular aggregation are not fully understood, we hypothesized that this form of cellular aggregation may provide a survival advantage. In this article, we characterize the mechanism by which EBV induces this protein and its expression on lymphoma tissue and cell lines and characterize EBV-infected cell lines in which CD226 has been knocked out.
Funding Information
  • HHS | NIH | National Cancer Institute (R01-CA140337)
  • HHS | NIH | National Cancer Institute (T32-CA009111)
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (5P30-AI064518)
  • HHS | NIH | National Institute of Dental and Craniofacial Research (R01-DE025994)

This publication has 40 references indexed in Scilit: